Pharma Commercial Mock
← All views·CI feed·API docs
AASCO
Meeting Library
ASCO Annual Meeting 2026 · Chicago, IL
53 shown of 6,470 total abstracts
  1. Abstract 14002026-06-04 · 15:45 CT · S100A
    Quality of life outcomes with Kisqali in patients with HR+ breast cancer
    S. Peters, T. Mok, N. Rizvi, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  2. Abstract 12922026-06-02 · 13:00 CT · E450
    Quality of life outcomes with Trodelvy in patients with TNBC
    C. Robert, H. Borghaei, S. Modi · Memorial Sloan Kettering Cancer Center
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  3. Abstract 16432026-06-02 · 18:15 CT · Hall B1
    Quality of life outcomes with Verzenio in patients with HR+ breast cancer
    R. Herbst, C. Robert, M. Krop, et al. · Peter MacCallum Cancer Centre
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  4. Abstract 17082026-06-05 · 21:15 CT · S100A
    KEYNOTE-501: Keytruda (pembrolizumab) maintenance in TNBC
    T. Mok, G. Curigliano, E. Winer, et al. · Johns Hopkins Kimmel Cancer Center
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  5. Abstract 16012026-06-02 · 16:45 CT · Arie Crown Theater
    Real-world effectiveness of Lynparza vs standard of care in HR+ breast cancer
    E. Winer, M. Krop, N. Rizvi, et al. · Dana-Farber Cancer Institute
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  6. Abstract 12182026-06-02 · 20:15 CT · S406
    Quality of life outcomes with Ibrance in patients with HR+ breast cancer
    T. Mok, C. Robert, J. Cortes · Princess Margaret Cancer Centre
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  7. Abstract 11732026-06-04 · 15:30 CT · E450
    Real-world effectiveness of Kisqali vs standard of care in HR+ breast cancer
    S. Peters, S. Tolaney · Stanford Cancer Institute
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  8. Abstract 17522026-06-02 · 14:30 CT · S406
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-344
    H. Borghaei, L. Paz-Ares, M. Krop · Karolinska Institute
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  9. Abstract 10712026-06-02 · 20:00 CT · Arie Crown Theater
    MONARCH-170: Verzenio (abemaciclib) maintenance in HR+ breast cancer
    J. Brahmer, R. Herbst, M.C. Garassino, et al. · UCSF Helen Diller Family Comprehensive Cancer Center
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  10. Abstract 11122026-06-04 · 21:30 CT · Hall B1
    Real-world effectiveness of Ibrance vs standard of care in HR+ breast cancer
    F. Andre, H. Rugo · Vall d'Hebron Institute of Oncology
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  11. Abstract 19002026-06-05 · 14:30 CT · S100A
    IMpower-54: Tecentriq (atezolizumab) 2L in TNBC
    T. Mok, C. Saura, N. Rizvi · Royal Marsden Hospital
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  12. Abstract 19572026-06-05 · 19:00 CT · Arie Crown Theater
    Quality of life outcomes with Tecentriq in patients with TNBC
    H. Borghaei, E. Winer, L. Paz-Ares · MD Anderson Cancer Center
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  13. Abstract 15702026-06-02 · 15:30 CT · Arie Crown Theater
    Long-term follow-up of Lynparza 2L for HR+ breast cancer: OlympiA-59
    H. Borghaei, E. Winer · Memorial Sloan Kettering Cancer Center
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  14. Abstract 10982026-06-05 · 16:00 CT · Hall B1
    Long-term follow-up of Verzenio 3L+ for HR+ breast cancer: MONARCH-600
    R. Herbst, L. Paz-Ares, J. Brahmer, et al. · Cleveland Clinic
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  15. Abstract 19602026-06-03 · 21:00 CT · E450
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-790 study)
    M. Reck, L. Paz-Ares · Peter MacCallum Cancer Centre
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  16. Abstract 18902026-06-04 · 14:00 CT · Hall B1
    Biomarker subgroup analysis of Lynparza in HR+ breast cancer (the OlympiA-563 study)
    S. Antonia, G. Curigliano, N. Rizvi, et al. · Institut Gustave Roussy
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  17. Abstract 17492026-06-04 · 16:45 CT · E450
    Long-term follow-up of Kisqali maintenance for HR+ breast cancer: MONALEESA-90
    A. Spira, S. Peters · Karolinska Institute
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  18. Abstract 11902026-06-03 · 13:45 CT · Arie Crown Theater
    Enhertu plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from DESTINY-Breast-567
    R. Herbst, G. Curigliano · Cleveland Clinic
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  19. Abstract 15862026-06-03 · 16:45 CT · S406
    Real-world effectiveness of Enhertu vs standard of care in HR+ breast cancer
    H. Borghaei, H. Rugo, F. Andre · Karolinska Institute
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  20. Abstract 12292026-06-01 · 18:00 CT · Arie Crown Theater
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-233 study)
    R. Herbst, M. Krop, N. Rizvi, et al. · Mayo Clinic
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  21. Abstract 10022026-06-03 · 16:00 CT · S100A
    ASCENT-890: Trodelvy (sacituzumab govitecan) neoadjuvant in TNBC
    C. Robert, P. Schmid, J. Brahmer, et al. · Dana-Farber Cancer Institute
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  22. Abstract 16622026-06-02 · 16:45 CT · Arie Crown Theater
    Long-term follow-up of Trodelvy maintenance for TNBC: ASCENT-330
    S. Modi, E. Winer, C. Saura · Cleveland Clinic
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  23. Abstract 11492026-06-05 · 13:00 CT · S406
    Biomarker subgroup analysis of Trodelvy in TNBC (the ASCENT-605 study)
    J. Cortes, R. Herbst, M. Reck, et al. · Cleveland Clinic
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  24. Abstract 15442026-06-05 · 20:00 CT · Hall B1
    Real-world effectiveness of Verzenio vs standard of care in HR+ breast cancer
    M. Krop, E. Winer, L. Paz-Ares · University of Chicago
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  25. Abstract 17602026-06-04 · 13:00 CT · S406
    Long-term follow-up of Ibrance 1L for HR+ breast cancer: PALOMA-687
    J. Cortes, S. Antonia, J. Brahmer, et al. · Johns Hopkins Kimmel Cancer Center
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  26. Abstract 13072026-06-05 · 14:45 CT · Arie Crown Theater
    Long-term follow-up of Kisqali neoadjuvant for HR+ breast cancer: MONALEESA-953
    H. Borghaei, E. Winer, S. Peters, et al. · Peter MacCallum Cancer Centre
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  27. Abstract 15062026-06-01 · 16:30 CT · E450
    Biomarker subgroup analysis of Tecentriq in TNBC (the IMpower-881 study)
    M. Reck, M.C. Garassino, P. Schmid, et al. · Royal Marsden Hospital
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  28. Abstract 14262026-06-02 · 19:30 CT · E450
    ASCENT-247: Trodelvy (sacituzumab govitecan) 1L in TNBC
    S. Tolaney, A. Spira, M. Reck · Vall d'Hebron Institute of Oncology
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  29. Abstract 11422026-06-02 · 20:15 CT · Hall B1
    MONALEESA-419: Kisqali (ribociclib) adjuvant in HR+ breast cancer
    G. Curigliano, N. Rizvi · Memorial Sloan Kettering Cancer Center
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  30. Abstract 17562026-06-02 · 20:45 CT · S406
    Kisqali plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from MONALEESA-84
    E. Winer, S. Tolaney · MD Anderson Cancer Center
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  31. Abstract 14152026-06-03 · 20:15 CT · E450
    PALOMA-309: Ibrance (palbociclib) maintenance in HR+ breast cancer
    H. Borghaei, L. Paz-Ares · Institut Gustave Roussy
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  32. Abstract 12822026-06-02 · 21:15 CT · Arie Crown Theater
    IMpower-988: Tecentriq (atezolizumab) 2L in TNBC
    M. Reck, M.C. Garassino · Vall d'Hebron Institute of Oncology
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  33. Abstract 14552026-06-05 · 20:45 CT · Hall B1
    ASCENT-500: Trodelvy (sacituzumab govitecan) 3L+ in TNBC
    M.C. Garassino, S. Antonia · Cleveland Clinic
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  34. Abstract 18202026-06-03 · 21:30 CT · Arie Crown Theater
    Ibrance plus chemotherapy in previously untreated HR+ breast cancer: updated analysis from PALOMA-314
    M. Reck, L. Paz-Ares, M. Krop · Karolinska Institute
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  35. Abstract 11522026-06-03 · 15:30 CT · Hall B1
    Biomarker subgroup analysis of Kisqali in HR+ breast cancer (the MONALEESA-581 study)
    T. Mok, S. Peters, M. Krop, et al. · University of Chicago
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  36. Abstract 18012026-06-04 · 13:15 CT · Arie Crown Theater
    Biomarker subgroup analysis of Tecentriq in TNBC (the IMpower-194 study)
    S. Antonia, M.C. Garassino, E. Winer, et al. · Vall d'Hebron Institute of Oncology
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  37. Abstract 13422026-06-05 · 14:15 CT · E450
    Real-world effectiveness of Keytruda vs standard of care in TNBC
    S. Modi, M.C. Garassino · Karolinska Institute
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  38. Abstract 11252026-06-04 · 18:30 CT · Hall B1
    DESTINY-Breast-269: Enhertu (trastuzumab deruxtecan) 3L+ in HR+ breast cancer
    M.C. Garassino, L. Paz-Ares, S. Peters, et al. · National Cancer Center Japan
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  39. Abstract 15512026-06-02 · 14:15 CT · S406
    Biomarker subgroup analysis of Tecentriq in TNBC (the IMpower-992 study)
    T. Mok, P. Schmid, M.C. Garassino, et al. · Memorial Sloan Kettering Cancer Center
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  40. Abstract 19112026-06-05 · 18:30 CT · S406
    Long-term follow-up of Ibrance 2L for HR+ breast cancer: PALOMA-945
    G. Curigliano, L. Paz-Ares, M.C. Garassino, et al. · Memorial Sloan Kettering Cancer Center
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  41. Abstract 13802026-06-04 · 16:45 CT · E450
    Trodelvy plus chemotherapy in previously untreated TNBC: updated analysis from ASCENT-999
    H. Borghaei, A. Spira, S. Modi, et al. · Chinese University of Hong Kong
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  42. Abstract 11752026-06-02 · 19:00 CT · S406
    MONALEESA-248: Kisqali (ribociclib) 2L in HR+ breast cancer
    H. Rugo, R. Herbst, L. Paz-Ares · Royal Marsden Hospital
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  43. Abstract 11972026-06-04 · 14:45 CT · Arie Crown Theater
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-98 study)
    H. Rugo, C. Robert, M. Reck, et al. · Mayo Clinic
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  44. Abstract 17472026-06-01 · 16:30 CT · S100A
    MONARCH-530: Verzenio (abemaciclib) 3L+ in HR+ breast cancer
    L. Paz-Ares, E. Winer, S. Tolaney, et al. · Cleveland Clinic
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  45. Abstract 10142026-06-02 · 15:00 CT · S406
    Long-term follow-up of Trodelvy maintenance for TNBC: ASCENT-430
    L. Paz-Ares, C. Robert · Memorial Sloan Kettering Cancer Center
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  46. Abstract 16122026-06-05 · 19:15 CT · S100A
    Long-term follow-up of Ibrance 1L for HR+ breast cancer: PALOMA-45
    S. Tolaney, P. Schmid · Chinese University of Hong Kong
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  47. Abstract 17012026-06-02 · 13:30 CT · Hall B1
    Quality of life outcomes with Enhertu in patients with HR+ breast cancer
    C. Saura, J. Cortes, M.C. Garassino, et al. · Karolinska Institute
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  48. Abstract 19002026-06-04 · 18:15 CT · Hall B1
    Long-term follow-up of Lynparza 3L+ for HR+ breast cancer: OlympiA-438
    A. Spira, F. Andre, P. Schmid, et al. · Peter MacCallum Cancer Centre
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  49. Abstract 12822026-06-02 · 20:00 CT · E450
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-267 study)
    F. Andre, S. Peters, J. Brahmer · National Cancer Center Japan
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  50. Abstract 17372026-06-05 · 18:15 CT · S100A
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-242 study)
    S. Peters, J. Brahmer, M. Reck, et al. · Princess Margaret Cancer Centre
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  51. Abstract 10052026-06-03 · 20:00 CT · Arie Crown Theater
    Biomarker subgroup analysis of Lynparza in HR+ breast cancer (the OlympiA-672 study)
    C. Saura, H. Borghaei · Memorial Sloan Kettering Cancer Center
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  52. Abstract 10732026-06-05 · 18:45 CT · S406
    Real-world effectiveness of Trodelvy vs standard of care in TNBC
    T. Mok, F. Andre, S. Tolaney, et al. · National Cancer Center Japan
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
  53. Abstract 10652026-06-01 · 18:00 CT · S406
    Real-world effectiveness of Tecentriq vs standard of care in TNBC
    S. Tolaney, C. Robert, M.C. Garassino · Chinese University of Hong Kong
    Clinical Science SymposiumBreast Cancer—Metastatic📄🖼️
© 2026 American Society of Clinical Oncology · Citations follow JCO supplement format:J Clin Oncol 44, 2026 (suppl 17; abstr XXXX). Demo mock.